^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesna

    Company:
    Generic mfg.
    Drug class:
    Antioxidant
    Related drugs:
    6d
    Transformation of a Testicular Teratoma to an Aggressive Primitive Neuroectodermal Tumor. (PubMed, Cureus)
    Treatment for the PNET included vincristine, doxorubicin, cyclophosphamide, and ifosfamide/etoposide mesna...The patient also underwent a tandem autologous stem cell transplant with carboplatin/etoposide conditioning and adjuvant etoposide and the subsequent PET/CT scan showed a response to the above treatment...The regimen for our patient yielded promising results. Our aim is to highlight a regimen that can be utilized for this rare aggressive neoplasm.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    10d
    CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=1, Terminated, Celularity Incorporated | N=52 --> 1 | Trial completion date: Feb 2025 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Feb 2024; for business reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cyclophosphamide • CYNK-101 • fludarabine IV • mesna • Proleukin (aldesleukin)
    20d
    A Study of N9 Chemotherapy in Children With Neuroblastoma (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna
    1m
    Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Memorial Sloan Kettering Cancer Center
    Trial completion date • Trial primary completion date
    |
    temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • mesna • dexrazoxane
    2ms
    IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Indapta Therapeutics, INC.
    New P1 trial
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • mesna • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
    2ms
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2024 --> Jul 2025
    Trial completion date
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • mesna • SJCAR19
    2ms
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    2ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting | N=52 --> 170
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    2ms
    High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • Promacta (eltrombopag) • busulfan • Nplate (romiplostim)
    3ms
    CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies (clinicaltrials.gov)
    P1, N=24, Recruiting, St. Jude Children's Research Hospital | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna
    3ms
    The synergistic effects of anoikis-related genes and EMT-related genes in the prognostic prediction of Wilms tumor. (PubMed, Front Mol Biosci)
    Paclitaxel and mesna were selected as potential chemotherapeutic drugs and adjuvant chemotherapeutic drugs for the WT high-risk group by using the Genomics of Drug Sensitivity in Cancer (GDSC) and cMAP compound libraries, respectively. Next, we selected NTRK2 as the hub gene, and in vitro experiments confirmed that its inhibition can significantly inhibit the proliferation and migration of tumor cells and promote late apoptosis. In summary, we screened out the potential biomarkers and chemotherapeutic drugs that can improve the prognosis of patients with WT.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    paclitaxel • mesna
    3ms
    CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov)
    P1, N=32, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy
    4ms
    Haploidentical HCT for Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=21, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim)
    4ms
    Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    4ms
    CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> May 2026 | Trial primary completion date: Jul 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy
    5ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=52, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    5ms
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
    Enrollment closed • Enrollment change
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    5ms
    Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I study. (PubMed, EClinicalMedicine)
    Three dose levels of PLD (Duomeisu®) were studied (30, 40, or 50 mg/m2) in combination with cyclophosphamide (1500 mg/m2), mesna (1500 mg/m2), and vincristine (1.5 mg/m2, maximum 2 mg) once every 3 weeks. 82203303], and the Basic and Applied Basic Research Foundation of Guangdong Province [No. 2021A1515110234].
    P1 data • Journal
    |
    TP53 (Tumor protein P53)
    |
    cyclophosphamide • pegylated liposomal doxorubicin • vincristine • mesna • Duomeisu (pegylated liposomal doxorubicin)
    6ms
    A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies (clinicaltrials.gov)
    P2, N=3, Terminated, St. Jude Children's Research Hospital | N=32 --> 3 | Trial completion date: Apr 2027 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2026 --> May 2024; Principal Investigator left institution
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • mesna • thiotepa • busulfan • cyclosporine
    6ms
    Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors (clinicaltrials.gov)
    P2, N=92, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    cisplatin • paclitaxel • ifosfamide • etoposide IV • bleomycin • mesna
    6ms
    CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies (clinicaltrials.gov)
    P1, N=24, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna
    7ms
    MESNA Injection for TMJ Internal Derangement (clinicaltrials.gov)
    P=N/A, N=60, Completed, Tanta University | Recruiting --> Completed | N=12 --> 60 | Trial completion date: Jun 2024 --> Mar 2024
    Trial completion • Enrollment change • Trial completion date
    |
    mesna
    8ms
    LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov)
    P1/2, N=42, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | N=30 --> 42
    Enrollment change
    |
    everolimus • cyclophosphamide • mesna
    9ms
    Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim) • methylprednisolone sodium succinate
    9ms
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • mesna • Neupogen (filgrastim)
    9ms
    High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • mesna • Promacta (eltrombopag) • busulfan • Nplate (romiplostim)
    9ms
    Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, M.D. Anderson Cancer Center | N=30 --> 21 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Metastases
    |
    cyclophosphamide • fludarabine IV • mesna • OBX-115 • acetazolamide
    9ms
    CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial • CAR T-Cell Therapy
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna
    9ms
    A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (clinicaltrials.gov)
    P3, N=225, Suspended, Children's Oncology Group | Active, not recruiting --> Suspended
    Trial suspension
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • GLI2 (GLI Family Zinc Finger 2)
    |
    TP53 wild-type
    |
    cisplatin • cyclophosphamide • vincristine • lomustine
    9ms
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    9ms
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=320, Recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    10ms
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Feb 2028 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    11ms
    A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (clinicaltrials.gov)
    P3, N=225, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • GLI2 (GLI Family Zinc Finger 2)
    |
    TP53 wild-type
    |
    cisplatin • cyclophosphamide • vincristine • lomustine
    11ms
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • humanised dinutuximab (Hu14.18K322A)
    12ms
    Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2024 --> Jan 2034 | Trial primary completion date: Jan 2024 --> Jan 2034
    Trial completion date • Trial primary completion date
    |
    carboplatin • ifosfamide • etoposide IV • mesna
    12ms
    OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov)
    P2, N=170, Recruiting, Center for International Blood and Marrow Transplant Research | Not yet recruiting --> Recruiting
    Enrollment open • Post-transplantation
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    12ms
    A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies (clinicaltrials.gov)
    P2, N=32, Recruiting, St. Jude Children's Research Hospital
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • mesna • thiotepa • busulfan • cyclosporine
    12ms
    A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc.
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • mesna • busulfan • Neupogen (filgrastim)
    1year
    MESNA Injection for TMJ Internal Derangement (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Tanta University
    Trial completion date • Trial primary completion date
    |
    mesna
    1year
    A Study of N9 Chemotherapy in Children With Neuroblastoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | N=15 --> 30
    Enrollment change
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna
    1year
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Washington University School of Medicine | Trial completion date: Aug 2027 --> Nov 2027 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    1year
    A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • mesna • busulfan • Neupogen (filgrastim)